Sarah A. Chase, PharmD identifies the most common ESBL-producing bacteria and common ESBL resistance genes, recognizes the use and limitations in using phenotypic and genotypic data to identify potential ESBL-E organisms and discusses clinical trial data and IDSA guidance to assist in the selection of appropriate antimicrobials for the treatment of ESBL-E infections .

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.